File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term depot-medroxyprogesterone acetate and bone mineral density

TitleLong-term depot-medroxyprogesterone acetate and bone mineral density
Authors
KeywordsBone loss
Bone mineral density
Depot-medroxyprogesterone acetate
Long-term
Issue Date1999
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraception
Citation
Contraception, 1999, v. 59 n. 1, p. 25-29 How to Cite?
AbstractThe association between long-term use of depot-medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) has been controversial, as seen in three case-control studies in New Zealand, Thailand, and the United Kingdom. In the present case-controlled study of BMD, a group of 67 Chinese women who had used DMPA from 5-15 years was compared with 218 women of the same age range who had not used any steroidal hormones. DMPA users were found to have a significantly lower BMD at lumbar vertebra (L2-4) (0.93 g/cm2), neck of femur (0.69 g/cm2), trochanter (0.59 g/cm2), and Ward's triangle (0.58 g/cm2), as compared with the control group, whose corresponding BMD values were 1.03 g/cm2, 0.83 g/cm2, 0.71 g/cm2, and 0.78 g/cm2, respectively (p <0.001). The average percentage of bone loss per year was estimated to be 1.1% in L2-4, 2.3% in neck of femur, 2.4% in trochanter, and 3.5% in Ward's triangle. The percentage of bone loss in L2-4 was found to be more pronounced with age. This study provided information that the use of DMPA in a Chinese group for >5 years is associated with bone loss, and a prospective study is needed to confirm these data, which are different from two case-control studies. | The effect of long-term use of depot medroxyprogesterone acetate (DMPA) on bone mineral density remains controversial. The present study compared bone mineral densities in 67 long-term (5 years or more) DMPA users recruited consecutively from the Hong Kong (China) Family Planning Association with those in 218 age-matched controls recruited from 8 family health service clinics in Hong Kong. Mean age was 42.8 years (range, 34-46 years) in the DMPA group and 40.0 years (range, 34-46 years) among controls. Body mass index, calcium intake, and smoking were similar in both groups. The median duration of DMPA use was 6 years (range, 5-15 years). Long-term DMPA users had significantly lower bone mineral densities than controls at the lumbar vertebra (0.93 vs. 1.03 g/sq. cm), neck of femur (0.69 vs. 0.83 g/sq. cm), trochanter (0.59 vs. 0.71 g/sq. cm), and Ward's triangle (0.58 vs. 0.78 g/sq. cm). The percentage of bone loss in L2-4 was more pronounced with increasing age. For each year of DMPA use, the decrease in bone mineral density was estimated to be 0.011 g/sq. cm (1.1%) in L2-4, 0.0193 g/sq. cm (2.3%) in the neck of femur, 0.0169 g/sq. cm (2.4%) in the trochanter, and 0.0277 g/sq. cm (3.5%) in Ward's triangle.
Persistent Identifierhttp://hdl.handle.net/10722/87372
ISSN
2015 Impact Factor: 2.788
2015 SCImago Journal Rankings: 1.557
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, OSen_HK
dc.contributor.authorTang, Gen_HK
dc.contributor.authorYip, Pen_HK
dc.contributor.authorLi, Ben_HK
dc.contributor.authorFan, Sen_HK
dc.date.accessioned2010-09-06T09:28:49Z-
dc.date.available2010-09-06T09:28:49Z-
dc.date.issued1999en_HK
dc.identifier.citationContraception, 1999, v. 59 n. 1, p. 25-29en_HK
dc.identifier.issn0010-7824en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87372-
dc.description.abstractThe association between long-term use of depot-medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) has been controversial, as seen in three case-control studies in New Zealand, Thailand, and the United Kingdom. In the present case-controlled study of BMD, a group of 67 Chinese women who had used DMPA from 5-15 years was compared with 218 women of the same age range who had not used any steroidal hormones. DMPA users were found to have a significantly lower BMD at lumbar vertebra (L2-4) (0.93 g/cm2), neck of femur (0.69 g/cm2), trochanter (0.59 g/cm2), and Ward's triangle (0.58 g/cm2), as compared with the control group, whose corresponding BMD values were 1.03 g/cm2, 0.83 g/cm2, 0.71 g/cm2, and 0.78 g/cm2, respectively (p <0.001). The average percentage of bone loss per year was estimated to be 1.1% in L2-4, 2.3% in neck of femur, 2.4% in trochanter, and 3.5% in Ward's triangle. The percentage of bone loss in L2-4 was found to be more pronounced with age. This study provided information that the use of DMPA in a Chinese group for >5 years is associated with bone loss, and a prospective study is needed to confirm these data, which are different from two case-control studies. | The effect of long-term use of depot medroxyprogesterone acetate (DMPA) on bone mineral density remains controversial. The present study compared bone mineral densities in 67 long-term (5 years or more) DMPA users recruited consecutively from the Hong Kong (China) Family Planning Association with those in 218 age-matched controls recruited from 8 family health service clinics in Hong Kong. Mean age was 42.8 years (range, 34-46 years) in the DMPA group and 40.0 years (range, 34-46 years) among controls. Body mass index, calcium intake, and smoking were similar in both groups. The median duration of DMPA use was 6 years (range, 5-15 years). Long-term DMPA users had significantly lower bone mineral densities than controls at the lumbar vertebra (0.93 vs. 1.03 g/sq. cm), neck of femur (0.69 vs. 0.83 g/sq. cm), trochanter (0.59 vs. 0.71 g/sq. cm), and Ward's triangle (0.58 vs. 0.78 g/sq. cm). The percentage of bone loss in L2-4 was more pronounced with increasing age. For each year of DMPA use, the decrease in bone mineral density was estimated to be 0.011 g/sq. cm (1.1%) in L2-4, 0.0193 g/sq. cm (2.3%) in the neck of femur, 0.0169 g/sq. cm (2.4%) in the trochanter, and 0.0277 g/sq. cm (3.5%) in Ward's triangle.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraceptionen_HK
dc.relation.ispartofContraceptionen_HK
dc.rightsContraception. Copyright © Elsevier Inc.en_HK
dc.subjectBone lossen_HK
dc.subjectBone mineral densityen_HK
dc.subjectDepot-medroxyprogesterone acetateen_HK
dc.subjectLong-termen_HK
dc.titleLong-term depot-medroxyprogesterone acetate and bone mineral densityen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0010-7824&volume=59&spage=25&epage=29&date=1998&atitle=Long-term+depot-medroxyprogesterone+acetate+and+bone+mineral+densityen_HK
dc.identifier.emailTang, G: gwktang@hkucc.hku.hken_HK
dc.identifier.emailYip, P: sfpyip@hku.hken_HK
dc.identifier.authorityTang, G=rp00328en_HK
dc.identifier.authorityYip, P=rp00596en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0010-7824(98)00144-9en_HK
dc.identifier.pmid10342083-
dc.identifier.scopuseid_2-s2.0-0033009026en_HK
dc.identifier.hkuros41126en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033009026&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume59en_HK
dc.identifier.issue1en_HK
dc.identifier.spage25en_HK
dc.identifier.epage29en_HK
dc.identifier.isiWOS:000079731100005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTang, OS=36881248500en_HK
dc.identifier.scopusauthoridTang, G=7401633864en_HK
dc.identifier.scopusauthoridYip, P=7102503720en_HK
dc.identifier.scopusauthoridLi, B=15767862000en_HK
dc.identifier.scopusauthoridFan, S=11639038000en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats